Your Patient Can't Find Tenofovir Alafenamide — Here's How to Help

When a patient with chronic hepatitis B reports they can't fill their Tenofovir Alafenamide (Vemlidy) prescription, it's more than an inconvenience — it's a clinical concern. The FDA boxed warning on Vemlidy specifically cautions against treatment interruptions, noting that discontinuation of anti-hepatitis B therapy can trigger severe acute exacerbations of hepatitis B.

This guide provides a practical, step-by-step approach for providers and clinic staff to help patients maintain access to their TAF-based therapy.

Current Availability Landscape

As of early 2026, Vemlidy is not in a formal FDA-declared shortage. However, real-world access challenges are common:

• Retail pharmacy stocking is limited — Vemlidy's high cost ($1,500-$1,800/month) and small patient volume mean most chain pharmacies don't carry it routinely
• No US generic exists — despite FDA approval for generic manufacture, no generic TAF monotherapy product is marketed domestically
• Insurance routing — many plans require specialty pharmacy dispensing, creating confusion when prescriptions are sent to retail locations
• TAF combination product demand — high demand for HIV products like Biktarvy and Descovy can occasionally affect broader TAF supply chains

For the full availability picture, see our provider shortage briefing.

Why Patients Can't Find It

Understanding the root causes helps target your intervention:

Pharmacy Doesn't Stock It

This is the most common scenario. The medication isn't unavailable from the manufacturer — the local pharmacy simply doesn't carry it. Solution: direct the patient to a pharmacy that does, or switch to a specialty pharmacy.

Insurance Requires Specialty Pharmacy

The patient's plan may only cover Vemlidy through a designated specialty pharmacy. A prescription at a retail location will be rejected. Solution: verify the patient's pharmacy benefit and route the prescription accordingly.

Prior Authorization Pending or Denied

Vemlidy frequently requires prior authorization. A pending PA means the pharmacy can't dispense even if they have stock. Solution: ensure the PA is submitted promptly and follow up on status.

Cost Barrier

Even with insurance, high co-pays at specialty tier can prevent patients from picking up their medication. Solution: enroll in Gilead's assistance programs.

What Providers Can Do: 5 Steps

Step 1: Verify Insurance Coverage and Pharmacy Network

Before the patient leaves your office, confirm:

• Is Vemlidy on the patient's formulary?
• What tier is it on?
• Is prior authorization required?
• Does the plan require a specialty pharmacy? If so, which one?

Having this information upfront prevents the most common fill failures.

Step 2: Submit Prior Authorization Proactively

Don't wait for a pharmacy rejection to trigger the PA process. If you know the patient's plan requires PA for Vemlidy, submit it at the time of prescribing. Key supporting documentation:

• Diagnosis of chronic HBV with compensated liver disease
• Baseline eGFR and any renal risk factors
• DXA results if available
• Prior TDF use/intolerance (if step therapy required)
• Clinical rationale for TAF over TDF

Step 3: Use Medfinder to Locate Stock

Medfinder for Providers provides real-time pharmacy availability data for Tenofovir Alafenamide. Integrating a quick Medfinder check into your prescribing workflow can:

• Identify pharmacies with Vemlidy in stock before sending the prescription
• Reduce callbacks from patients reporting fill failures
• Provide patients with specific pharmacy recommendations at the point of care

Step 4: Enroll Patients in Financial Assistance

Gilead offers two key programs:

• Co-pay Assistance Program: For commercially insured patients. May reduce co-pay to $0. Enrollment: 1-855-769-7284 or through the patient's specialty pharmacy.
• Advancing Access Program: For uninsured or underinsured patients. Provides Vemlidy at no cost. Application: gileadadvancingaccess.com or 1-800-226-2056. Translation services available in Chinese, Korean, and Vietnamese.

Proactively connecting patients with these programs at the time of prescribing eliminates a major barrier to medication access.

Step 5: Have a Bridging Strategy Ready

For situations where Vemlidy truly cannot be obtained quickly, have a documented bridging protocol:

• First-line bridge: Tenofovir Disoproxil Fumarate (TDF) 300 mg daily — same active metabolite, widely available as generic ($30-$80/month). Increase renal and bone monitoring.
• Alternative bridge: Entecavir 0.5 mg daily (treatment-naive) or 1 mg daily (lamivudine-resistant). Preferred if renal function is the reason for TAF over TDF.
• Duration: Bridge until TAF is secured; schedule follow-up within 2-4 weeks to reassess.

Alternative Agents Reference

For patients who need a longer-term switch, the primary alternatives to Tenofovir Alafenamide for chronic HBV include:

• Tenofovir Disoproxil Fumarate (Viread): 300 mg daily. Generic available. More renal/bone toxicity than TAF. Most pharmacologically similar option.
• Entecavir (Baraclude): 0.5-1 mg daily. Generic available. Minimal renal effects. Not first-choice in lamivudine-resistant patients.
• Lamivudine (Epivir-HBV): 100 mg daily. High resistance rates limit long-term use. Low cost. Suitable for short-term bridging only.

Share our patient-facing guide on alternatives to Tenofovir Alafenamide with patients exploring options.

Workflow Tips for Clinic Staff

• Add a formulary check step to your new prescription workflow for Vemlidy — verify coverage before the patient leaves
• Bookmark Medfinder for Providers on clinic computers for quick availability searches
• Create a PA template for Vemlidy with pre-populated clinical justification fields to speed the process
• Track Gilead assistance enrollment — flag patients who haven't been connected to co-pay or patient assistance programs
• Set refill reminders — prompt patients to request refills 7-10 days before running out to allow time for ordering

Final Thoughts

Helping patients maintain access to Tenofovir Alafenamide requires proactive effort, but the clinical stakes make it worthwhile. Treatment interruptions in chronic hepatitis B carry real risks, and providers are uniquely positioned to prevent them.

By verifying coverage upfront, leveraging Medfinder for Providers for real-time stock data, enrolling patients in assistance programs, and having a bridging strategy ready, your practice can dramatically reduce fill failures and keep patients on track.

For additional resources, see our provider shortage briefing and guide to helping patients save money on Tenofovir Alafenamide.